Tislelizumab for Resectable Ultra-low Rectal Cancer

This study focuses on treating patients with a type of rectal cancer called ultra-low rectal adenocarcinoma. It specifically targets individuals whose cancer is resectable, meaning it can potentially be removed by surgery, and who have not previously received treatment. The trial aims to explore the effectiveness of adding a drug called tislelizumab to the standard treatment of chemoradiotherapy followed by chemotherapy. Understanding whether tislelizumab can improve outcomes, such as preserving the anus and delaying or avoiding more invasive surgery, is crucial for enhancing the quality of life for patients with this challenging condition. Participants in the study receive a combination of chemotherapy and radiation therapy, and then some receive additional cycles of chemotherapy with or without tislelizumab. Treatment success is measured by how well the cancer responds, focusing on whether surgery can be avoided and how long patients remain cancer-free. Those who do not respond fully to the initial treatment are advised to undergo a surgery called total mesorectal excision. The study tracks various outcomes like how many people can keep their organ intact over one to three years and overall survival rates, providing important data on the potential benefits and risks of the treatment strategy.